Nuvalent reports net loss of $81.9M for FY22; cash runway into H2 2025

Nuvalent, Inc.

Cash, cash equivalents and marketable securities $472.2M as of Dec 31, 2022; expected to fund operations into H2 2025.
Net loss of $26.1M in Q4 2022 and $81.9M for full year 2022; R&D expenses $63.7M (FY) vs $35.6M in 2021.
Pipeline progress: NVL-520 Phase 1 data supportive of best-in-class profile in ROS1+ NSCLC; NVL-655 Phase 1 enrolling; NVL-330 (HER2 exon20) nominated as development candidate.
Leadership promotions: Henry Pelish to SVP Drug Discovery; John Soglia to SVP Translational Development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nuvalent, Inc. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

announced its financial results for the quarter and year ended December 31, 2023, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvalent, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008282

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.